Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD20-specific CAR T cell therapy in relapsed/refractory B cell non-Hodgkin lymphomas
NCT03277729Phase 2Active, not recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2017
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Dose-limiting Toxicities Rate at 28 days. Started Dec 2017; status: active, not recruiting.
02
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03277729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277729.